This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Supporting companies to grow at The Oxford Science Park

Supporting companies to grow at The Oxford Science Park

16 Dec 2024

The Oxford Science Park is committed to supporting companies to grow at the Park. We listen to and work closely with current and prospective occupiers, digging into the detail of their requirements to deliver optimal space for office and lab working. Being able to grow at the Park spares companies the upheaval of a costly move and enables them to remain focused on core business activities. In addition, they benefit from the consistency of... Read more

Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development

Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development

10 Dec 2024

Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, have announced an extension to their research collaboration to find novel targeting peptides for radiopharmaceutical delivery. This collaboration expands upon a previous agreement signed between the companies in April 2023 whereby technology synergies have enabled the... Read more

EIT and University of Oxford join forces in a transformative strategic alliance with an investment of £130m

EIT and University of Oxford join forces in a transformative strategic alliance with an investment of £130m

03 Dec 2024

University of Oxford and the Ellison Institute of Technology (EIT) announced today that they are entering a long-term strategic alliance to develop the solutions and future leaders needed to tackle some of the greatest and most enduring challenges facing humanity. This will involve an overall investment of £130m from EIT. The alliance was confirmed in a signing ceremony which took place at Oxford's Clarendon Building. The University of... Read more

EVENT: Imaging Membrane Proteins in Real Time

EVENT: Imaging Membrane Proteins in Real Time

26 Nov 2024

Come along to an event hosted by Sitryx to hear expert insights from The Kennedy Insitute of Rheumatology and The Rosalind Franklin Institute. Read more

Theolytics doses first patient in trial to treat ovarian cancer

Theolytics doses first patient in trial to treat ovarian cancer

26 Nov 2024

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC). Ovarian Cancer is one of the leading causes of cancer related deaths among women. It exhibits a stromal rich, immune-suppressed TME,... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More